A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-022-04430-6
Abstract: BRCA1 or BRCA2 mutated cancers (BRCAmut) have intrinsic sensitivity to PARP inhibitors due to deficiency in homologous recombination-mediated DNA repair. There are similarities between BRCAmut and BRCAwt ovarian and basal-like breast cancers. This phase I… read more here.
Keywords: brca1 brca2; cancer; brca2 mutated; bid ... See more keywords
Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Sign Up to like & getrecommendations! Published in 2017 at "Breast"
DOI: 10.1016/j.breast.2017.04.006
Abstract: Specific alkylators may allow synthetic lethality among patients with germline BRCA1/2-mutations related cancers. The tetrahydroisoquinolone trabectedin administered at 1.3 mg/m2 as a 3-h intravenous infusion every 3 weeks showed activity in patients with pretreated metastatic breast… read more here.
Keywords: mutated patients; brca2 carriers; brca2 mutated; brca2 ... See more keywords
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
Sign Up to like & getrecommendations! Published in 2018 at "Cell reports"
DOI: 10.1016/j.celrep.2018.03.038
Abstract: BRCA1/2-mutated ovarian cancers (OCs) are defective in homologous recombination repair (HRR) of double-strand breaks (DSBs) and thereby sensitive to platinum and PARP inhibitors (PARPis). Multiple PARPis have recently received US Food and Drug Administration (FDA)… read more here.
Keywords: mutated carcinomas; brca2 mutated; resistance; platinum parp ... See more keywords